BerGenBio

Selective AXL inhibitors

Home  /  Events  /  BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019

BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019

Share This Post

Add to Calendar 12/09/2019 6:00 pm Europe/Oslo BerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019 For more information visit: https://www.bergenbio.com/bergenbio-to-present-clinical-data-from-phase-ii-combination-trial-of-bemcentinib-and-ldac-trial-in-elderly-aml-patients-at-ash-2019-2/

Poster presentation at ASH 2019

Date: Monday 9th December 2019

Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Time, Location: 6:00 PM – 8:00 PM, Orange County Convention Center, Hall B

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.